Financials Myriad Genetics, Inc.

Stocks

MYGN

US62855J1043

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq Other stock markets 16:00:00 2026-08-03 EDT			5-day change	1st Jan Change
3.020 ^USD	+5.59%		-44.59%	-50.89%

07-30	Myriad Genetics, Inc., Q2 2026 Earnings Call, Jul 30, 2026
07-30	Myriad Genetics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Projected Income Statement: Myriad Genetics, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net sales ¹	690.6	678.4	753.2	837.6	824.5	805.9	851.2	903.7
Change	-	-1.77%	11.03%	11.21%	-1.56%	-2.26%	5.62%	6.17%
EBITDA ¹	71.9	-21	-6.3	40.4	38.9	1.962	14.61	53.23
Change	-	-129.21%	70%	741.27%	-3.71%	-94.96%	644.76%	264.36%
EBIT ¹	9.1	-32.8	-25.5	21.8	15.1	-78.54	-62.88	-58.2
Change	-	-460.44%	22.26%	185.49%	-30.73%	-620.13%	19.94%	7.44%
Interest Paid ¹	-5.9	-3.2	-2.9	-2.8	-10.5	-9.25	-10.57	-
Earnings before Tax (EBT) ¹	-57.1	-140.6	-262.2	-123.5	-395.1	-63.75	-50.98	-47.29
Change	-	-146.23%	-86.49%	52.9%	-219.92%	83.86%	20.04%	7.23%
Net income ¹	-27.2	-112	-263.3	-127.3	-365.9	-93.19	-64.66	-47.29
Change	-	-311.76%	-135.09%	51.65%	-187.43%	74.53%	30.61%	26.86%
Announcement Date	2/24/22	2/28/23	2/27/24	2/24/25	2/23/26	-	-	-

¹USD in Million

Estimates

Fiscal Period: December	2021 Q3	2021 Q4	2022 Q1	2022 Q2	2022 Q3	2022 Q4	2023 Q1	2023 Q2	2023 Q3	2023 Q4	2024 Q1	2024 Q2	2024 Q3	2024 Q4	2025 Q1	2025 Q2	2025 Q3	2025 Q4	2026 Q1	2026 Q2	2026 Q3	2026 Q4	2027 Q1	2027 Q2	2027 Q3	2027 Q4	2028 Q1	2028 Q2
Net sales ¹	167.3	160.8	164.9	179.3	156.4	177.8	181.2	183.5	191.9	196.6	202.2	211.5	213.3	210.6	195.9	213.1	205.7	209.8	200.4	190.7	203.8	209.7	207	207.5	214.2	219.4	220	224.7
Change	-	-3.89%	2.55%	8.73%	-12.77%	13.68%	1.91%	1.27%	4.58%	2.45%	2.85%	4.6%	0.85%	-1.27%	-6.98%	8.78%	-3.47%	1.99%	-4.48%	-4.84%	6.86%	2.89%	-1.3%	0.25%	3.26%	2.43%	0.26%	2.14%
EBITDA ¹	12.8	13.4	10.2	7.3	-17.6	-10.7	-20.5	-4.2	1.2	10.1	4.4	11.9	14.1	10.6	-0.1	14.5	10.3	14.3	-4.5	-16.9	5.339	11.45	-3.074	-2.745	3.337	5.494	-	-
Change	-	4.69%	-23.88%	-28.43%	-341.1%	39.2%	-91.59%	79.51%	128.57%	741.67%	-56.44%	170.45%	18.49%	-24.82%	-100.94%	14,600%	-28.97%	38.83%	-131.47%	-275.56%	131.59%	114.49%	-126.85%	10.71%	221.57%	64.65%	-	-
EBIT ¹	-1.4	0.1	-2.8	4.5	-20.6	-13.9	-21.9	-6.8	-2.2	5.7	-0.6	7.4	9.5	5.6	-5.5	8.6	4.1	7.8	-10.6	-21.7	-21.2	-18.73	-16.4	-18.3	-14.1	-12.8	-	-
Change	-	107.14%	-2,900%	260.71%	-557.78%	32.52%	-57.55%	68.95%	67.65%	359.09%	-110.53%	1,333.33%	28.38%	-41.05%	-198.21%	256.36%	-52.33%	90.24%	-235.9%	-104.72%	2.3%	11.64%	12.46%	-11.59%	22.95%	9.22%	-	-
Charge d'intérêts ¹	-0.9	-0.4	-0.9	-0.6	-0.8	-0.9	-0.5	-0.5	-1	-0.9	-0.5	-0.8	-0.8	-0.7	-0.8	-1.5	-3.8	-4.4	-4.1	-	-1	-1.1	-2.25	-2.25	-2.2	-2.2	-	-
Earnings before Tax (EBT) ¹	39.8	-43.5	-26.4	-17.9	-44.2	-52.1	-52.6	-116.1	-61.2	-32.3	-25.9	-37.2	-21.2	-39.1	-29.4	-330.6	-26.2	-8.9	-34.1	-42.6	-5.062	3.563	-21.36	-17.64	-8.48	-6.69	-16.98	-8.652
Change	-	-209.3%	39.31%	32.2%	-146.93%	-17.87%	-0.96%	-120.72%	47.29%	47.22%	19.81%	-43.63%	43.01%	-84.43%	24.81%	-1,024.49%	92.08%	66.03%	-283.15%	-24.93%	88.12%	170.39%	-699.35%	17.41%	51.92%	21.11%	-153.78%	49.04%
Net income ¹	24.6	-7.6	-20.5	-14.1	-35.1	-42.3	-54.7	-116.1	-61.3	-31.2	-26	-36.7	-22.1	-42.5	-0.1	-330.5	-27.4	-7.9	-34.1	-43.2	-26.53	-14.72	-22.8	-20.46	-16.32	-11.79	-16.98	-8.652
Change	-	-130.89%	-169.74%	31.22%	-148.94%	-20.51%	-29.31%	-112.25%	47.2%	49.1%	16.67%	-41.15%	39.78%	-92.31%	99.76%	-330,400%	91.71%	71.17%	-331.65%	-26.69%	38.59%	44.52%	-54.94%	10.28%	20.23%	27.74%	-43.96%	49.04%
Announcement Date	11/2/21	2/24/22	5/5/22	8/4/22	11/1/22	2/28/23	5/3/23	8/3/23	11/6/23	2/27/24	5/7/24	8/6/24	11/7/24	2/24/25	5/6/25	8/5/25	11/3/25	2/23/26	5/5/26	7/30/26	-	-	-	-	-	-	-	-

¹USD in Million

Estimates

Forecast Balance Sheet: Myriad Genetics, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Net Debt	-340	-115	-102	-62.8	-29.7	-	-	-
Change	-	66.18%	11.3%	38.43%	52.71%	-	-	-
Announcement Date	2/24/22	2/28/23	2/27/24	2/24/25	2/23/26	-	-	-

Estimates

Cash Flow Forecast: Myriad Genetics, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027
CAPEX ¹	18	45.3	63.2	19	15.6	17.2	18.9
Change	-	151.67%	39.51%	-69.94%	-17.89%	10.26%	9.88%
Free Cash Flow (FCF) ¹	162.2	-151.6	-174.1	-27.7	-13.8	-	-
Change	-	-193.46%	-14.84%	84.09%	50.18%	100%	-
Announcement Date	2/24/22	2/28/23	2/27/24	2/24/25	2/23/26	-	-

¹USD in Million

Estimates

Forecast Financial Ratios: Myriad Genetics, Inc.

Fiscal Period: December	2021	2022	2023	2024	2025	2026	2027	2028
Profitability
EBITDA Margin (%)	10.41%	-3.1%	-0.84%	4.82%	4.72%	0.24%	1.72%	5.89%
EBIT Margin (%)	1.32%	-4.83%	-3.39%	2.6%	1.83%	-9.75%	-7.39%	-6.44%
EBT Margin (%)	-8.27%	-20.73%	-34.81%	-14.74%	-47.92%	-7.91%	-5.99%	-5.23%
Net margin (%)	-3.94%	-16.51%	-34.96%	-15.2%	-44.38%	-11.56%	-7.6%	-5.23%
FCF margin (%)	23.49%	-22.35%	-23.11%	-3.31%	-1.67%	-	-	-
FCF / Net Income (%)	-596.32%	135.36%	66.12%	21.76%	3.77%	-	-	-
Profitability
ROA	0.1%	-1.92%	-1.93%	1.15%	-	-	-	-
ROE	0.15%	-12.08%	-2.71%	1.68%	1.08%	-20.7%	-	-
Financial Health
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Debt / Free cash flow	-	-	-	-	-	-	-	-
Capital Intensity
CAPEX / Current Assets (%)	2.61%	6.68%	8.39%	2.27%	1.89%	2.13%	2.22%	-
CAPEX / EBITDA (%)	25.03%	-215.71%	-1,003.17%	47.03%	40.1%	876.84%	129.37%	-
CAPEX / FCF (%)	11.1%	-29.88%	-36.3%	-68.59%	-113.04%	-	-	-
Items per share
Cash flow per share ¹	0.2333	-1.319	-1.339	-0.096	0.0194	0.1263	0.4245	-
Change	-	-665.23%	-1.53%	92.83%	120.21%	550.82%	236.19%	-
Dividend per Share ¹	-	-	-	-	-	-	-	-
Change	-	-	-	-	-	-	-	-
Book Value Per Share ¹	12.1	10.91	8.712	7.679	3.936	-	-	-
Change	-	-9.83%	-20.14%	-11.86%	-48.75%	-	-	-
EPS ¹	-0.35	-1.39	-3.18	-1.41	-3.95	-1.165	-0.67	-0.485
Change	-	-297.14%	-128.78%	55.66%	-180.14%	70.51%	42.49%	27.61%
Nbr of stocks (in thousands)	79,855	81,034	88,669	91,035	93,214	95,650	95,650	95,650
Announcement Date	2/24/22	2/28/23	2/27/24	2/24/25	2/23/26	-	-	-